(Medical Xpress) -- King’s researchers in the Division of Cancer Studies have developed new technology for the identification and validation of microRNA (miRNA) targets in research and clinical diagnostics, resulting in an exclusive licence agreement with Sigma Life Science announced today. Patented by King’s Business, this technology is now being co-developed with Sigma Life Science into a kit ready for commercialization.
